Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Multiple Myeloma 52Leukemia, Myeloid, Acute 49Lymphoma, Non-Hodgkin 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Lymphoma 37Leukemia 35Hodgkin Disease 35Myelodysplastic Syndromes 33Lymphoma, Mantle-Cell 20Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Burkitt Lymphoma 17Lymphoma, Follicular 12Hematologic Neoplasms 12Neoplasms, Plasma Cell 11Congenital Abnormalities 11Lymphoma, B-Cell, Marginal Zone 10Leukemia, Biphenotypic, Acute 9Breast Neoplasms 9Myeloproliferative Disorders 8Lymphoma, Large-Cell, Immunoblastic 8Anemia, Refractory, with Excess of Blasts 8Recurrence 7Leukemia, Myelomonocytic, Juvenile 7Leukemia, Myelomonocytic, Chronic 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Graft vs Host Disease 6Sarcoma 5

Interventions

eltrombopag 7romiplostim 6Cytarabine 3Carboplatin 3Platelet Transfusion 2Cyclophosphamide 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2sodium thiosulfate 1pegfilgrastim 1oprelvekin 1ofatumumab 1lusutrombopag 1fludarabine 1etoposide phosphate 1avatrombopag 1angiotensin I (1-7) 1Tranexamic Acid 1Stem Cell Transplantation 1Sirolimus 1Saline Solution 1Rituximab 1Microarray Analysis 1Lenalidomide 1Interleukin-11 1Ifosfamide 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Gemcitabine 1Flow Cytometry 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thrombocytopenia × Granulocyte Colony-Stimulating Factor × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡